Wells Fargo & Company MN grew its holdings in MEDNAX Inc (NYSE:MD) by 74.9% in the 4th quarter, HoldingsChannel reports. The fund owned 838,882 shares of the company’s stock after purchasing an additional 359,288 shares during the quarter. Wells Fargo & Company MN’s holdings in MEDNAX were worth $44,830,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in the business. APG Asset Management N.V. grew its holdings in shares of MEDNAX by 24.9% during the third quarter. APG Asset Management N.V. now owns 63,300 shares of the company’s stock worth $2,729,000 after buying an additional 12,600 shares in the last quarter. Nationwide Fund Advisors grew its holdings in shares of MEDNAX by 9.7% during the third quarter. Nationwide Fund Advisors now owns 513,389 shares of the company’s stock worth $22,137,000 after buying an additional 45,472 shares in the last quarter. Aperio Group LLC grew its holdings in shares of MEDNAX by 76.1% during the third quarter. Aperio Group LLC now owns 41,688 shares of the company’s stock worth $1,798,000 after buying an additional 18,012 shares in the last quarter. Peregrine Capital Management LLC bought a new position in shares of MEDNAX during the third quarter worth about $8,315,000. Finally, Pictet Asset Management Ltd. grew its holdings in shares of MEDNAX by 4.1% during the third quarter. Pictet Asset Management Ltd. now owns 35,600 shares of the company’s stock worth $1,535,000 after buying an additional 1,400 shares in the last quarter. Institutional investors own 95.12% of the company’s stock.
In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.40% of the company’s stock.
MEDNAX Inc (NYSE:MD) opened at $54.98 on Thursday. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $72.13. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $5,150.00, a P/E ratio of 15.94, a P/E/G ratio of 1.38 and a beta of 0.31.
MEDNAX (NYSE:MD) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.83 by $0.04. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The firm had revenue of $910.82 million during the quarter, compared to analysts’ expectations of $884.55 million. During the same period in the prior year, the firm posted $1.00 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. equities analysts predict that MEDNAX Inc will post 4.03 EPS for the current fiscal year.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.